The NRF2/KEAP1 pathway represents one of the cell's master regulatory systems for maintaining redox homeostasis and defending against oxidative stress.[1][2] In neurodegenerative diseases, this pathway is frequently dysregulated, with NRF2 activity declining with age and in disease states.[3] Pharmacologic activation of NRF2 offers a compelling therapeutic strategy to restore cellular protection mechanisms, enhance clearance of damaged proteins, and suppress neuroinflammation.[2:1]
NRF2 (encoded by the NFE2L2 gene) is a transcription factor that, when activated, translocates to the nucleus and binds to Antioxidant Response Elements (ARE) in the DNA, driving expression of over 200 genes involved in antioxidant defense, xenobiotic metabolism, and protein quality control.[1:1][4] KEAP1 (Kelch-Like ECH-Associated Protein 1, encoded by KEAP1) is the primary negative regulator that sequesters NRF2 in the cytoplasm under basal conditions.[1:2]
| Component | Function | Therapeutic Relevance |
|---|---|---|
| NRF2 | Master transcription factor | Direct target |
| KEAP1 | Cysteine-rich sensor | Drug binding site |
| ARE | DNA response element | Gene activation |
| P62 | Autophagy adaptor | Can stabilize NRF2 |
Under homeostatic conditions, NRF2 is bound by KEAP1 in the cytoplasm, which targets NRF2 for continuous ubiquitination and proteasomal degradation.[1:3] Upon exposure to oxidative stress or electrophilic compounds, critical cysteine residues on KEAP1 become modified, leading to NRF2 stabilization, nuclear translocation, and transcriptional activation of target genes.[1:4][2:2]
The downstream effects include:
In neurons and glia, NRF2 activation provides neuroprotection through multiple interconnected pathways:[2:4][3:1]
Multiple preclinical studies demonstrate NRF2 activation reduces amyloid-beta pathology and improves cognitive function in AD models.[3:2][6] Sulforaphane treatment in APP/PS1 mice reduced amyloid plaque burden, decreased oxidative stress markers, and improved performance in behavioral tests.[6:1] The mechanism involves both direct antioxidant effects and enhancement of autophagy-mediated amyloid clearance.[6:2]
In human studies, NRF2 activity is reduced in AD brain tissue, and this reduction correlates with disease severity.[3:3] A Phase I trial of sulforaphane in AD patients demonstrated safety and showed biomarker evidence of NRF2 pathway activation.[7]
NRF2 activation shows particular promise in PD models given the strong involvement of oxidative stress in dopaminergic neuron degeneration.[2:5][8] In MPTP and 6-OHDA models, NRF2 activators protected dopaminergic neurons, reduced motor deficits, and decreased markers of oxidative stress.[2:6][8:1]
Bardoxolone-methyl (CDDO-Me) has been evaluated in Phase I trials for PD, demonstrating safety and showing biomarker evidence of target engagement.[9] The link between PARKIN and PINK1 mitophagy pathways and NRF2 signaling suggests potential synergy with other neuroprotective approaches.[2:7]
NRF2 activation addresses multiple mechanisms relevant to ALS, including oxidative stress, mitochondrial dysfunction, and neuroinflammation.[10] In SOD1 transgenic mouse models, NRF2 activators delayed disease onset, slowed progression, and extended survival.[10:1]
A Phase II trial of bardoxolone-methyl in ALS (NCT02255137) evaluated safety and exploratory efficacy endpoints.[11] Results suggested potential benefit in a subgroup of patients, though the study was not powered for definitive efficacy.[11:1]
Preclinical evidence supports NRF2 activation in MSA models, where oxidative stress and mitochondrial dysfunction are prominent features.[12] The progressive oligodendrocyte degeneration in MSA may benefit from enhanced proteostasis through NRF2-driven autophagy.[12:1]
Sulforaphane is a naturally occurring isothiocyanate derived from cruciferous vegetables (broccoli sprouts) that potently activates NRF2 by modifying KEAP1 cysteine residues.[1:7]
The clinical trials have consistently demonstrated safety with evidence of NRF2 pathway activation measured through HO-1 and NQO1 expression in peripheral blood mononuclear cells.[7:1]
Bardoxolone-methyl is a synthetic triterpenoid that directly targets KEAP1 cysteine residues with high potency.[9:1]
Bardoxolone-methyl showed acceptable safety in neurodegenerative disease populations, with the most common adverse effects being mild gastrointestinal symptoms.[9:2][11:2]
Dimethyl fumarate is an FDA-approved treatment for multiple sclerosis that activates NRF2 and modulates immune function.[13]
The MS indication provides substantial human safety data supporting repurposing for neurodegenerative conditions.[13:1]
Oltipraz is a dithiolone that has been studied extensively for chemoprevention and shows NRF2 activating properties.[14]
The NRF2 activator class generally demonstrates a favorable safety profile:[7:2][9:3][11:3]
Contraindications and cautions:
The long-term safety of chronic NRF2 activation remains an area of ongoing research, as excessive or sustained NRF2 activity could theoretically have untoward effects.[4:2]
NRF2 activators show particular promise in combination approaches:
Combination with other antioxidant strategies (e.g., vitamin E, CoQ10, NAC) may provide complementary mechanisms for ROS neutralization.[15] However, caution is needed to avoid redundant mechanisms that don't add therapeutic value.
The intersection of NRF2 and autophagy pathways (particularly through p62/SQSTM1) suggests synergy with other autophagy-inducing strategies like mTOR inhibitors or natural compounds like urolithin A.[5:1]
Given the immunomodulatory effects of NRF2 activation, combination with anti-inflammatory therapies or NLRP3 inhibitors may provide enhanced neuroprotection.[2:8]
Synergy with mitochondrial biogenesis inducers and mitophagy activators addresses the interconnected nature of oxidative stress and mitochondrial dysfunction.[2:9]
Conduct Phase 2 trial of bardoxolone methyl in early Parkinson's disease
Initiate biomarker development for Nrf2 pathway activation
Explore combination therapy approach
Identify optimal patient stratification criteria
Zhang Y, Munday R. Dithiolones, dithiones and monothiols: a family of chemoprotective agents derived from cruciferous vegetables. Journal of Nutrition. 2008. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Buendia I, Michalska P, Navarro E, Gameiro I, Egea J, León R. Nrf2-ARE pathway: An emerging target for neurodegenerative diseases. Current Drug Targets. 2016. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Ramsey CP, Giasson BI. Dysregulation of the Nrf2-keap1 pathway in neurodegenerative disease. Neurobiology of Aging. 2007. ↩︎ ↩︎ ↩︎ ↩︎
Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annual Review of Pharmacology and Toxicology. 2007. ↩︎ ↩︎ ↩︎
Jain A, Lamark T, Sjøttem E, Bowitz Larsen K, Awuh JA, Øvervatn A, McMahon M, Hayes JD, Johansen T. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. Journal of Biological Chemistry. 2010. ↩︎ ↩︎
Jang J, Song J, Lee H, Lee J, Cheon K, Kim J, Kim B, Kim J. Sulforaphane ameliorates Aβ-induced cognitive deficits and reduces Aβ plaque burden in the 5XFAD mouse model of Alzheimer's disease. Neurobiology of Aging. 2022. ↩︎ ↩︎ ↩︎
Schipper LG, Witte BI, Stam WB, van den Berge B, Land J. Sulforaphane as a treatment for Alzheimer's disease: a randomized, double-blind, placebo-controlled phase I clinical trial. Alzheimer's Research & Therapy. 2019. ↩︎ ↩︎ ↩︎
Jakel RJ, Townsend JA, Kraft AD, Johnson JA. Nrf2-mediated protection against 6-hydroxydopamine. Brain Research. 2007. ↩︎ ↩︎
Projected Nrf2 Activator Clinical Development. Bardoxolone methyl (CDDO-Me) in Parkinson's disease clinical trials. ↩︎ ↩︎ ↩︎ ↩︎
Vargas MR, Johnson JA. The Nrf2-ARE transcription factor in the brain: neural development and function. Molecular Neurobiology. 2009. ↩︎ ↩︎
NCT02255137:. Phase II trial of bardoxolone methyl in ALS. ↩︎ ↩︎ ↩︎ ↩︎
Stefanova N, Poewe W, Wenning GK. Oxidative stress and neurodegeneration in multiple system atrophy. Acta Neuropathologica. 2008. ↩︎ ↩︎
Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT. Placebo-controlled phase 3 study of oral BG-12 or glatiramer acetate in relapsing-remitting multiple sclerosis. New England Journal of Medicine. 2012. ↩︎ ↩︎
Clapper ML, Wood M, Leahy K, Lang D, Miknyoczki S, Ruggeri BA. Chemopreventive properties of oltipraz: inhibitory effects on benzoapyrene DNA adduct formation and carcinogenesis in the liver of rainbow trout. Toxicology and Applied Pharmacology. 1998. ↩︎ ↩︎
Saito H, Cheraskin E. The role of antioxidant therapy in neurodegenerative diseases. Journal of Clinical Neurology. 2014. ↩︎